問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

高憲立

Recruiting

List

20Cases

2025-08-29 - 2031-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2025-09-30 - 2032-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2026-02-01 - 2029-02-28

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-10-01 - 2030-06-30

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2024-02-01 - 2028-12-31

Phase III

Active
A Phase III, Randomised, Double-blind, Placebo-controlled, Event-driven Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Renal Outcomes and Cardiovascular Mortality in Participants with Chronic Kidney Disease and High Blood Pressure

  • Condition/Disease

    Chronic Kidney Disease and High Blood Pressure

  • Test Drug

    tablet

Participate Sites
11Sites

Recruiting11Sites

2023-09-01 - 2027-07-31

Phase II

Completed
Randomised Study for Double-blind, Placebo-controlled Evaluation of a Single Intravenous Infusion of BI 765845 and Partially-blinded Evaluation of a Single Bolus Administration of BI 765845 on Top of Standard of Care in Patients With Acute Myocardial Infarction

  • Condition/Disease

    Myocardial Infarction

  • Test Drug

    注射用凍晶粉末

Participate Sites
2Sites

Recruiting2Sites

2020-06-11 - 2022-11-02

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2018-07-01 - 2035-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2018-10-24 - 2024-03-31

Phase III

SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity

  • Condition/Disease

    Obesity

  • Test Drug

    Semaglutide B 3.0 mg/mL PDS290 or Semaglutide placebo

Participate Sites
6Sites

Recruiting4Sites

Terminated2Sites

謝宜璋
Linkou Chang Gung Medical Foundation

Division of Cardiovascular Diseases

2021-09-01 - 2022-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting10Sites

Terminated2Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB